ARDX Ardelyx Inc

USD 6.44 -0.11 -1.679389
Icon

Ardelyx Inc (ARDX) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Neutral

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 6.44

-0.11 (-1.68)%

USD 1.50B

3.74M

USD 12.50(+94.10%)

USD 3.58 (-44.41%)

Icon

ARDX

Ardelyx Inc (USD)
COMMON STOCK | NSD
USD 6.44
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Neutral

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 1.50B

USD 3.58 (-44.41%)

USD 6.44

Ardelyx Inc (ARDX) Stock Forecast

Show ratings and price targets of :
USD 12.50
(+94.10%)

Based on the Ardelyx Inc stock forecast from 6 analysts, the average analyst target price for Ardelyx Inc is USD 12.50 over the next 12 months. Ardelyx Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Ardelyx Inc is Neutral, which is based on 5 positive signals and 5 negative signals. At the last closing, Ardelyx Inc’s stock price was USD 6.44. Ardelyx Inc’s stock price has changed by -12.62% over the past week, -17.86% over the past month and +31.70% over the last year.

No recent analyst target price found for Ardelyx Inc
No recent average analyst rating found for Ardelyx Inc

Company Overview Ardelyx Inc

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with...Read More

https://www.ardelyx.com

400 Fifth Avenue, Waltham, MA, United States, 02451

267

December

USD

United States

Adjusted Closing Price for Ardelyx Inc (ARDX)

Loading...

Unadjusted Closing Price for Ardelyx Inc (ARDX)

Loading...

Share Trading Volume for Ardelyx Inc Shares

Loading...

Compare Performance of Ardelyx Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for ARDX

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Ardelyx Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc +0.38 (+0.10%) USD107.38B 29.93 21.06

ETFs Containing ARDX

Symbol Name ARDX's Weight Expense Ratio Price(Change) Market Cap

Frequently Asked Questions About Ardelyx Inc (ARDX) Stock

Based on ratings from 6 analysts Ardelyx Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 8 buy, sell and hold ratings.

Unfortunately we do not have enough data on ARDX's stock to indicate if its a good dividend stock.

Based on targets from 6 analysts, the average taret price for ARDX is USD 12.50 over the next 12 months. The maximum analyst target price is USD 15 while the minimum anlayst target price is USD 9.

Unfortunately we do not have enough data on ARDX's stock to indicate if its overvalued.

The last closing price of ARDX's stock was USD 6.44.

The most recent market capitalization for ARDX is USD 1.50B.

Based on targets from 6 analysts, the average taret price for ARDX is projected at USD 12.50 over the next 12 months. This means that ARDX's stock price may go up by +94.10% over the next 12 months.

We can't find any ETFs which contains Ardelyx Inc's stock.

As per our most recent records Ardelyx Inc has 267 Employees.

Ardelyx Inc's registered address is 400 Fifth Avenue, Waltham, MA, United States, 02451. You can get more information about it from Ardelyx Inc's website at https://www.ardelyx.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...